Last updated: September 28, 2026
Perampanel, marketed by Eisai as Fycompa, is a mature antiseizure medicine with durable commercial performance. Its revenue base has been supported by expanded age indications, global availability, and continued use in partial-onset seizures and primary generalized tonic-clonic seizures. The principal long-term risk is generic entry rather than biosimilar competition. The core composition patent has expired or reached the end of its effective term in major markets, while method-of-use, formulation, and manufacturing patents can affect the timing and commercial scope of generic launches.
What is perampanel and how is Fycompa used?
Perampanel is an orally active, noncompetitive AMPA glutamate receptor antagonist. It is sold as Fycompa tablets and oral suspension.
The U.S. Food and Drug Administration approved Fycompa in October 2012 as adjunctive therapy for partial-onset seizures. FDA later approved use in primary generalized tonic-clonic seizures. The current U.S. label covers:
| Attribute |
Fycompa profile |
| Active ingredient |
Perampanel |
| Brand owner |
Eisai Inc. and Eisai Co., Ltd. |
| Drug class |
Antiseizure medicine |
| Mechanism |
Noncompetitive AMPA receptor antagonist |
| U.S. approval |
October 2012 |
| Main indications |
Partial-onset seizures; primary generalized tonic-clonic seizures |
| Dosage forms |
Tablets; oral suspension |
| Typical dosing |
Once daily, generally 2 mg to 12 mg depending on indication and tolerability |
| U.S. regulatory category |
Small-molecule prescription drug |
| Biosimilar pathway |
Not applicable |
| Main competitive threat |
Generic perampanel |
The once-daily regimen differentiates perampanel from several older antiseizure drugs that require multiple daily doses. Its principal commercial limitations are behavioral and psychiatric adverse reactions, drug-drug interactions, titration requirements, and competition from established therapies such as levetiracetam, lamotrigine, lacosamide, brivaracetam, and topiramate.[1]
How has the perampanel market developed?
Perampanel entered a crowded antiseizure market but established a differentiated position through its AMPA-antagonist mechanism and broad geographic launch. Eisai expanded the product through additional indications and pediatric approvals.
Key milestones include:
| Date |
Event |
| 2012 |
FDA approval for adjunctive treatment of partial-onset seizures |
| 2012 |
European authorization for adjunctive treatment of partial-onset seizures |
| 2015 |
U.S. approval for primary generalized tonic-clonic seizures |
| 2016 |
Approval in Japan |
| 2017 onward |
Expansion into younger pediatric populations in several markets |
| 2020 onward |
Continued international commercialization and lifecycle management |
| 2023-2025 |
Increasing exposure to generic-entry risk as core patent protection aged |
Market demand is relatively defensive. Epilepsy patients often remain on established therapy for long periods, and physicians may avoid switching a patient who is seizure-controlled. That persistence supports branded revenue after loss of exclusivity, although payer substitution can produce rapid price erosion once an approved generic becomes broadly available.
The product is most exposed in the United States, Japan, and major European markets. The commercial trajectory is less dependent on new patient growth than on retention, indication coverage, pricing, geographic mix, and the timing of generic competition.
What has been the financial trajectory of Fycompa?
Eisai reports Fycompa as part of product sales and does not publicly disclose a complete standalone income statement for the product. Public annual reports indicate that global Fycompa revenue increased from the low-to-mid ¥40 billion range in the early 2020s to approximately the mid-¥50 billion range more recently, although reported growth varies by fiscal year, currency, and regional performance.[2]
Fycompa revenue drivers
The main financial drivers have been:
- Expanded indications and pediatric use.
- Continued prescription retention among patients who respond to treatment.
- Growth outside the United States.
- Foreign-exchange translation effects.
- Stable branded pricing before broad generic substitution.
- Eisai’s ability to defend or delay generic launches through listed patents and litigation.
Fycompa has not reached the revenue scale of Eisai’s oncology and Alzheimer’s products. It is still strategically relevant because its commercial infrastructure is mature, manufacturing requirements are comparatively manageable, and the product generates recurring cash flow without the development cost of a new molecular entity.
Revenue trajectory by lifecycle stage
| Lifecycle stage |
Financial effect |
| Initial U.S. launch |
Rapid uptake from specialist prescribing and unmet-mechanism positioning |
| Indication expansion |
Increased addressable population and improved prescription retention |
| International expansion |
Diversified revenue and reduced dependence on the U.S. market |
| Mature branded period |
Slower unit growth, with pricing and persistence supporting sales |
| Initial generic entry |
Lower net price and possible formulary displacement |
| Post-generic period |
Revenue depends on residual brand loyalty, authorized generic strategy, and geographic patent differences |
Eisai does not disclose Fycompa-specific operating profit, gross margin, or promotional spending in a way that permits a precise product-level profitability calculation. The product is likely to have a high incremental margin relative to its development-stage economics, but that margin should not be confused with total corporate profitability because manufacturing, regulatory, commercial, and shared overhead allocations are not publicly separated.
When does perampanel lose exclusivity?
Perampanel’s effective exclusivity differs by country because patent terms, pediatric extensions, regulatory exclusivity, and litigation settlements are jurisdiction-specific.
The core composition patent associated with perampanel is U.S. Patent No. 6,949,571, covering oxo-pyrrolidine derivatives that include perampanel-related chemical subject matter. Its ordinary U.S. patent term reached the end of its life in 2023, subject to applicable patent-term adjustment and pediatric exclusivity.[3]
The practical exclusivity position is more complex than the expiration of the composition patent:
| Protection type |
Commercial relevance |
| Composition patent |
Protects the active pharmaceutical ingredient and is usually the strongest barrier to early generic entry |
| Method-of-use patents |
Can restrict labels directed to particular seizure types or patient populations |
| Formulation patents |
May protect oral suspension, dosage forms, excipients, or release characteristics |
| Manufacturing patents |
Can increase the cost or complexity of generic production |
| Regulatory exclusivity |
Can delay approval even after patent expiration |
| Pediatric exclusivity |
Can extend certain listed patent protections by six months in the United States |
Generic applicants can seek approval with a Paragraph IV certification against listed patents. A Paragraph IV filing does not automatically authorize launch. It can trigger patent litigation and a statutory 30-month stay of FDA approval under the Hatch-Waxman framework, subject to the statute and litigation history.[4]
What is the Orange Book status of Fycompa?
The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with an approved U.S. drug. Fycompa’s relevant Orange Book analysis should distinguish between:
- patents covering the active ingredient;
- patents covering specific methods of use;
- patents covering formulations or dosage forms; and
- any remaining regulatory exclusivity.
The core composition patent is no longer the principal long-term barrier in the United States. The remaining risk is whether later-listed patents, pediatric extensions, litigation outcomes, or settlement terms delay approval or limit the labeling available to generic products.
A generic applicant may pursue one of three broad strategies:
- File a Paragraph IV certification and challenge listed patents.
- File with a section viii statement and omit patented indications from the label.
- Wait for relevant patents and exclusivities to expire.
A section viii strategy can permit a generic to enter for unprotected indications while avoiding a patented use. Its commercial value depends on whether pharmacies and payers substitute that product for the branded product despite the narrower label.
Which patents protect perampanel formulations and methods of use?
The patent estate is more valuable when it covers commercially important use cases rather than peripheral product characteristics.
Composition protection
Composition patents provide the strongest protection because they prevent generic manufacturers from marketing the active ingredient itself. Once the composition patent expires, a generic can generally seek approval for the same active ingredient, subject to remaining listed patents.
Method-of-use protection
Method patents can cover the treatment of specific seizure types, age groups, dosing regimens, or clinical populations. Their practical strength depends on:
- whether the patented use is central to prescribing;
- whether a non-infringing label is commercially viable;
- whether induced-infringement theories are likely to succeed;
- whether the patent claims survive validity challenges.
For perampanel, method-of-use claims covering generalized tonic-clonic seizures or particular epilepsy populations may have more commercial relevance than narrow dosing claims.
Formulation protection
Fycompa is available as tablets and oral suspension. Formulation patents may cover:
- suspension stability;
- excipient combinations;
- particle size;
- dosage uniformity;
- manufacturing processes; and
- specific concentrations or administration formats.
Formulation patents generally do not prevent all generic tablet entry if the generic can develop a non-infringing tablet. They have greater value when they protect the only commercially practical pediatric or dysphagia-friendly presentation.
Which companies are challenging Fycompa patents?
Generic competition is expected from companies with established oral-solid-dose and specialty-pharmacy capabilities. Potential participants include large generic manufacturers such as Teva, Viatris, Sandoz, Sun Pharma, Lupin, Dr. Reddy’s, Zydus, and Aurobindo, subject to actual ANDA filings and FDA approval status.
The existence of a generic manufacturer in the market does not establish that it has filed a Paragraph IV challenge. The relevant evidence is an ANDA litigation complaint, FDA approval record, Orange Book entry, or a publicly disclosed settlement.
Publicly disclosed information does not establish a single definitive industry-wide launch date for all generic perampanel products. Entry can occur in stages, with one or more authorized or independent generics entering before broad multisource substitution.
What generic entry risks exist for perampanel?
The generic-entry risk is high in the long term and moderate during the transition period.
Base-case scenario
The most likely commercial pattern is:
- One or more generic approvals after resolution of remaining patent barriers.
- Limited initial competition from a small number of manufacturers.
- Progressive formulary substitution.
- Declining net sales and price.
- Continued residual branded demand from patients and physicians who prefer the branded product.
Accelerated erosion scenario
Revenue could fall rapidly if several generic manufacturers launch near the same time. This outcome would increase pharmacy substitution and reduce Eisai’s ability to defend brand pricing.
Delayed-entry scenario
Revenue could remain resilient if:
- litigation delays approval;
- later patents survive challenge;
- generic labels omit commercially important indications;
- only a small number of suppliers launch;
- supply constraints limit generic availability; or
- Eisai uses an authorized-generic or brand-protection strategy.
For a mature oral small molecule, the usual long-term outcome is materially lower price rather than complete disappearance of demand. Brand revenue can persist, but it generally becomes a smaller fraction of the pre-generic market.
How does perampanel compare with competing antiseizure drugs?
| Drug |
Manufacturer or major originator |
Mechanism or profile |
Commercial comparison |
| Perampanel |
Eisai |
AMPA antagonist; once daily |
Differentiated mechanism, mature brand, generic risk |
| Levetiracetam |
UCB originator |
SV2A ligand |
Broad use, extensive generic competition, low price |
| Brivaracetam |
UCB |
High-affinity SV2A ligand |
Newer branded alternative, premium pricing |
| Lacosamide |
UCB |
Sodium-channel modulator |
Strong partial-onset seizure presence, generic competition |
| Lamotrigine |
GSK originator |
Sodium-channel modulation |
Broad indications and established generic use |
| Topiramate |
Janssen originator |
Multiple mechanisms |
Low-cost generic with broad utilization |
Perampanel’s competitive advantage is mechanism and once-daily dosing. Its disadvantage is the presence of behavioral adverse-event warnings and a higher branded cost than many generic alternatives. Once generic perampanel becomes widely available, price will become less of a disadvantage, but the drug will still compete with low-cost generic therapies with longer prescribing histories.
What is the biosimilar risk for perampanel?
There is no biosimilar risk because perampanel is a small-molecule drug, not a biologic. The relevant regulatory pathway is an abbreviated new drug application under the Hatch-Waxman framework.
This distinction matters commercially. Generic entrants can rely on pharmaceutical equivalence and bioequivalence rather than undertaking the clinical comparability program typically associated with biosimilars. That lowers development costs and can support multiple entrants after patent barriers fall.
Does perampanel have major licensing or partnership exposure?
Eisai discovered and developed perampanel and has retained the central commercial role. Public disclosures do not identify a material royalty burden or a major third-party licensing arrangement that would determine the product’s post-expiry economics.
The principal financial variables are therefore product sales, manufacturing cost, distribution expense, litigation spending, and the cost of maintaining regulatory registrations across markets.
What patent litigation affects Fycompa?
Patent litigation risk is concentrated in the United States and depends on ANDA filings. The major legal questions are likely to include:
- validity of later-listed method or formulation patents;
- infringement by generic labels;
- whether a generic can use a section viii carve-out;
- the scope of any pediatric exclusivity;
- the enforceability of settlement agreements; and
- the timing of FDA approval after litigation.
A Paragraph IV case can delay approval even where the generic ultimately prevails. Conversely, a settlement can establish a licensed entry date that is earlier than the full expiration of all listed patents. Settlement terms may include a launch date, authorized-generic restrictions, supply arrangements, or releases of patent claims.
No publicly established settlement date should be treated as the universal generic-entry date for all jurisdictions or all generic manufacturers. Each applicant’s regulatory and litigation position can differ.
What is the geographic coverage of perampanel protection?
Patent and exclusivity risk varies across the United States, Europe, Japan, and emerging markets.
| Region |
Main commercial issue |
| United States |
Orange Book patents, Paragraph IV litigation, pediatric exclusivity, pharmacy substitution |
| European Union |
National validation and enforcement of European patents, centralized marketing authorization, country-specific reimbursement |
| Japan |
Patent term, reexamination and regulatory rules, domestic pricing controls |
| China |
Local patent filings, national regulatory approval, procurement pricing |
| Latin America |
Variable patent enforcement, registration timing, and public-sector tender pricing |
| Other markets |
Earlier generic entry may coexist with continued branded sales in regulated markets |
A global generic launch is unlikely to occur on one uniform date. Generic products can enter lower-barrier markets while U.S., Japanese, or selected European rights remain active.
How strong is the perampanel patent estate?
The estate is strongest when evaluated historically and weaker when evaluated against the product’s remaining commercial life.
| Factor |
Assessment |
| Core composition protection |
Historically strong, but largely exhausted in major markets |
| Method-of-use protection |
Potentially meaningful if claims cover commercially important indications |
| Formulation protection |
Relevant to oral suspension and pediatric use, but less likely to block all tablet competition |
| Manufacturing protection |
May raise generic development costs without preventing all entry |
| Regulatory exclusivity |
Limited compared with the original launch period |
| Litigation leverage |
Dependent on remaining listed patents and the timing of ANDA challenges |
| Long-term durability |
Moderate to weak relative to a product with unexpired composition protection |
Perampanel remains commercially defensible as a brand, but its patent estate is unlikely to support indefinite premium pricing. The economic center of gravity has shifted from exclusivity creation to lifecycle management and post-generic retention.
Key Takeaways
- Fycompa is Eisai’s branded perampanel product and was first approved in the United States in 2012.
- Revenue has remained in the approximate ¥50 billion annual range in recent years, supported by indication expansion and international sales.
- Eisai does not disclose complete product-level profit data, so standalone margin and cash-flow estimates require assumptions.
- Perampanel has no biosimilar risk. Its main threat is generic substitution.
- The core composition patent reached the end of its ordinary U.S. term in 2023, while later patents and regulatory protections can affect entry timing.
- Method-of-use and formulation patents may delay or narrow generic competition but are less powerful than composition protection.
- The likely post-generic outcome is substantial price erosion, with residual branded demand in some patients and markets.
- Geographic entry will be uneven because patent, regulatory, reimbursement, and litigation conditions differ by country.
- Fycompa’s future value depends more on brand persistence, generic timing, and cost control than on further exclusivity expansion.
FAQs About Perampanel Market and Patent Risk
Is generic perampanel available in the United States?
Generic availability depends on FDA approval, remaining listed patents, litigation, and commercial launch decisions. An approved ANDA does not necessarily mean that a product has reached pharmacies.
What is the annual revenue of Fycompa?
Eisai’s public reporting places recent global Fycompa sales broadly in the mid-¥50 billion range, but the company does not provide a complete standalone product profit statement.
Is perampanel protected by a biologic exclusivity period?
No. Perampanel is a small molecule and follows the generic-drug pathway rather than the biosimilar pathway.
Can a generic market perampanel for only one seizure indication?
Yes. A generic applicant may use a section viii statement to omit a patented method of use from its labeling, subject to FDA approval and applicable patent law.
What is the biggest commercial risk to Eisai from perampanel?
The largest risk is multisource generic entry that produces rapid price reductions and pharmacy substitution in the United States and other major markets.
References
- U.S. Food and Drug Administration. (2024). Fycompa (perampanel) prescribing information.
- Eisai Co., Ltd. (2024). Annual report and financial results for the fiscal year ended March 31, 2024.
- United States Patent and Trademark Office. (2005). U.S. Patent No. 6,949,571: 2-oxo-1-pyrrolidine derivatives.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
